Denali Therapeutics is a biopharmaceutical company that discovers, develops, and commercializes medicines for serious diseases of the brain and central nervous system by overcoming the blood-brain barrier through its proprietary TransportVehicle platform, which uses Fc-domain engineering to deliver large molecules such as enzymes, oligonucleotides, and antibodies across this biological barrier via receptor-mediated transcytosis. The company operates three therapeutic franchises—enzyme replacement therapies for lysosomal storage diseases, antisense oligonucleotides for neurodegenerative conditions like Alzheimer's disease, and brain-penetrant antibodies for neurodegenerative and oncologic indications—with programs in rare genetic diseases and prevalent neurological conditions. Denali generates revenue from rare disease therapeutic launches and partnerships with pharmaceutical companies including Biogen, Takeda, and Sanofi, while planning to expand into larger neurodegenerative markets by leveraging strategic partnerships that bring global commercial infrastructure to its pipeline programs.